FunPep Company Limited [4881.T]
TOKYO, May 07 (Pulse News Wire) – FunPep Company Limited (4881.T) announced today that the final observation day for its Phase I clinical trial of allergy vaccine FPP004X, aimed at treating hay fever, has concluded. The trial involved healthy adults and patients with seasonal allergies, assessing the safety, tolerance, and immunogenicity of FPP004X through repeated intramuscular injections.
Data collection and analysis will continue, with preliminary results expected to be disclosed in the third quarter of 2026 (July to September). The Phase I study consisted of two parts: Part 1 included low-dose and high-dose cohorts among healthy volunteers, while Part 2 tested the vaccine's efficacy against cedar pollen exposure in allergic rhinitis patients. Hay fever affects approximately 20% of the population in Japan, with symptoms such as sneezing, runny nose, nasal congestion, and eye itching. Government efforts aim to address this widespread issue affecting millions of citizens.
FPP004X works by inducing antibody production against Immunoglobulin E (IgE) within the body, which is known to trigger allergic reactions upon binding to allergens like pollen. By promoting sustained anti-IgE antibody generation, FPP004X could offer a convenient treatment option for alleviating symptoms throughout the pollen season. The company signed an option agreement with Shionogi & Co., Ltd. in March 2024, granting exclusive rights for global research, development, and commercialization across all diseases.
🟢 Confidence: High AI-translated content.